Side Effects of Tigecycline
Critical Safety Warning: Increased Mortality Risk
Tigecycline carries an FDA black-box warning for numerically higher all-cause mortality compared to alternative antibiotics across multiple infection types, with an adjusted risk difference of 0.6% (95% CI 0.1–1.2). 1 This mortality signal was observed in clinical trials for complicated skin and soft tissue infections, intra-abdominal infections, diabetic foot infections, and hospital-acquired pneumonia, though the underlying cause remains unclear. 2, 1
Most Common Adverse Effects (Frequency-Based)
Gastrointestinal Effects (Very Common)
- Nausea occurs in 26% of patients (17% mild, 8% moderate, 1% severe), typically during the first 1–2 days of therapy. 1
- Vomiting affects 18% of patients (11% mild, 6% moderate, 1% severe). 1
- Diarrhea occurs in 12% of patients. 1
- Abdominal pain, dyspepsia, and anorexia are also common. 2, 1
- Nausea and vomiting are dose-dependent, with incidence reaching 65% at higher doses versus 18% at lower doses. 3
- Discontinuation due to nausea or vomiting occurs in approximately 1% of patients. 1
Hepatic Effects (Common)
- Elevated liver function tests (LFTs) occur frequently, with increases in AST (4%), ALT (5%), alkaline phosphatase (3%), and bilirubin (2%). 2, 1
- LFT abnormalities in tigecycline-treated patients occur more frequently in the post-therapy period. 1
- Hepatic cholestasis and jaundice have been reported post-marketing. 1
- Hepatotoxicity is significantly correlated with AST, GGT levels, and prolonged hospitalization. 4
Hematologic Effects (Common)
- Prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) are common. 2, 1
- Coagulopathy manifests as dose-dependent prolongation of PT/aPTT and reduced fibrinogen levels, with tigecycline acting on both extrinsic and intrinsic coagulation pathways. 5
- Blood fibrinogen decrease shows a very strong signal (ROR = 1714.078). 6
- Thrombocytopenia occurs in 75% of treated patients, particularly in older individuals, and typically reverses within 5 days of discontinuation. 7
- Anemia affects 5% of patients. 1
Dermatologic Effects (Common)
- Pruritus and rash occur in 3% of patients. 2, 1
- Stevens-Johnson syndrome has been reported post-marketing. 1, 8
Metabolic Effects (Common)
- Hypoglycemia (including symptomatic cases in diabetic and non-diabetic patients). 2, 1
- Hypoproteinemia (5%), hyponatremia (2%), and hypocalcemia. 1
- Elevated amylase (3%) and blood urea nitrogen (3%). 2, 1
Infectious Complications (Common)
- Sepsis/septic shock reported more frequently with tigecycline (2%) versus comparators (1%). 1
- Infection-related serious adverse reactions occur in 7% versus 6% with comparators. 1
- Pneumonia and abscess formation (2%). 1
Neurologic Effects (Common)
Vascular Effects (Common)
- Phlebitis (3%) and thrombophlebitis at injection sites. 2, 1
- Injection site reactions including inflammation, pain, edema, and phlebitis. 1
Serious Post-Marketing Adverse Events
- Anaphylactic reactions have been reported. 1
- Acute pancreatitis is a recognized serious adverse effect. 1, 8
- Clostridium difficile-associated diarrhea (CDAD) can range from mild diarrhea to fatal colitis. 1
Absolute Contraindications
- Hypersensitivity to tigecycline or any tetracycline-class antibiotic. 2, 9
- Children under 8 years of age due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia. 2, 9, 1
- Pregnancy (Category D) due to evidence of fetal harm in animal studies, including decreased fetal weights, skeletal anomalies, and fetal loss. 2, 9, 1
- Breastfeeding, as tigecycline is excreted in milk. 2, 9, 1
Special Warnings and Precautions
Monotherapy Caution in Intestinal Perforation
- Monotherapy should be avoided in patients with complicated intra-abdominal infections secondary to intestinal perforation, as 6 tigecycline-treated patients with perforation developed sepsis/septic shock versus 2 comparator-treated patients. 1
Tetracycline-Class Effects
- Photosensitivity, pseudotumor cerebri (benign intracranial hypertension), and anti-anabolic effects (increased BUN, azotemia, acidosis, hyperphosphatemia) may occur. 1
Coagulation Monitoring
- Prothrombin time or other anticoagulation tests should be monitored if tigecycline is co-administered with warfarin. 1
- Overdose and prolonged use should be avoided to prevent severe coagulopathy and bleeding. 5
Hepatic and Renal Impairment
- No dose adjustment is required for renal impairment. 2, 9
- In severe hepatic impairment (Child-Pugh class C), reduce the maintenance dose by 50%. 10
- Drug clearance disorders can develop in patients with liver and/or renal dysfunction, requiring close monitoring of coagulation function. 5
Oral Contraceptive Interaction
- Concurrent use may render oral contraceptives less effective. 1
Common Pitfalls to Avoid
- Do not use tigecycline as first-line therapy when alternative agents are available, given the mortality signal. 11, 9, 12
- Avoid use in bacteremia, as tigecycline achieves low serum concentrations (Cmax ≈ 0.87 mg/L), limiting efficacy. 9, 3
- Monitor for breakthrough infections and progression of the original infection vigilantly. 12
- Consider combination therapy (for synergism or enhanced coverage) rather than monotherapy when tigecycline use is warranted. 9, 12
- Closely monitor coagulation parameters (PT, aPTT, fibrinogen) and platelet counts, especially in older patients and those receiving prolonged therapy. 5, 7
- Antiemetic premedication or gradual dose escalation from 25 mg daily can mitigate nausea. 3